Literature DB >> 22789499

Pre-XDR & XDR in MDR and Ofloxacin and Kanamycin resistance in non-MDR Mycobacterium tuberculosis isolates.

Amita Jain1, Pratima Dixit, Rajendra Prasad.   

Abstract

Resistance to second line anti tubercular drugs is a cause of serious concern. The present study reports the prevalence of Ofloxacin (OFX) and Kanamycin (KM) resistance in Mycobacterium tuberculosis isolates from cases of pulmonary tuberculosis, who received anti tubercular treatment for >4 weeks in past. Of total 438 enrolled patients, 361 were culture positive for M. tuberculosis, of which, 95 (26.3%) were OFX resistant & 49 (13.5%) were KM resistant. Total 130 isolates were Multidrug resistant, of which, 55 (42.3%) were resistant to either OFX or KM (Pre-XDR) & 11 (8.5%) were resistant to both KM & OFX (XDR). Resistance to quinolones & aminoglycosides should be routinely assessed in areas endemic for tuberculosis.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22789499     DOI： 10.1016/j.tube.2012.05.010

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN： 1472-9792            Impact factor:   3.131


  11 in total

1.  A study on pre-XDR & XDR tuberculosis & their prevalent genotypes in clinical isolates of Mycobacterium tuberculosis in north India.

Authors:  Parul Singhal; Pratima Dixit; Pooja Singh; Indu Jaiswal; Mastan Singh; Amita Jain
Journal:  Indian J Med Res       Date:  2016-03       Impact factor: 2.375

Review 2.  Extensively drug-resistant tuberculosis in India: Current evidence on diagnosis & management.

Authors:  Rajendra Prasad; Abhijeet Singh; Viswesvaran Balasubramanian; Nikhil Gupta
Journal:  Indian J Med Res       Date:  2017-03       Impact factor: 2.375

3.  Kanamycin Sulphate Loaded PLGA-Vitamin-E-TPGS Long Circulating Nanoparticles Using Combined Coating of PEG and Water-Soluble Chitosan.

Authors:  Sanaul Mustafa; V Kusum Devi; Roopa S Pai
Journal:  J Drug Deliv       Date:  2017-03-02

Review 4.  Prevalence of drug-resistant pulmonary tuberculosis in India: systematic review and meta-analysis.

Authors:  Vishal Goyal; Vijay Kadam; Prashant Narang; Vikram Singh
Journal:  BMC Public Health       Date:  2017-10-17       Impact factor: 3.295

5.  Frequency and implications of ofloxacin resistance among previously treated tuberculosis patients.

Authors:  Jyoti Arora; Gavish Kumar; Ajoy Kumar Verma; Manpreet Bhalla; Ritu Singhal; Rohit Sarin; Vithal Prasad Myneedu
Journal:  J Epidemiol Glob Health       Date:  2017-05-24

6.  Drug-resistant tuberculosis: is India ready for the challenge?

Authors:  Soumya Chatterjee; Husain Poonawala; Yogesh Jain
Journal:  BMJ Glob Health       Date:  2018-08-10

7.  High degree of fluoroquinolone resistance among pulmonary tuberculosis patients in New Delhi, India.

Authors:  Rohini Sharma; Surendra Kumar Sharma; Binit Kumar Singh; Abhenil Mittal; Prahlad Kumar
Journal:  Indian J Med Res       Date:  2019-01       Impact factor: 2.375

8.  Prevalence of Extensively Drug Resistant Tuberculosis among Archived Multidrug Resistant Tuberculosis Isolates in Zimbabwe.

Authors:  Tichaona Sagonda; Lucy Mupfumi; Rumbidzai Manzou; Beauty Makamure; Mqondisi Tshabalala; Lovemore Gwanzura; Peter Mason; Reggie Mutetwa
Journal:  Tuberc Res Treat       Date:  2014-05-20

9.  2025 too short time to eliminate tuberculosis from India.

Authors:  Rajendra Prasad; Nikhil Gupta; Amitabh Banka
Journal:  Lung India       Date:  2017 Sep-Oct

10.  Second-line Drug Resistance Characterization in Mycobacterium tuberculosis by Genotype MTBDRsl Assay.

Authors:  Sunil Sethi; Priyanka Agarwal; Rajiv Khaneja; Naresh Kumar; Nitin Kumar; Jagesh Chandna; Ashutosh Nath Aggarwal; Rakesh Yadav
Journal:  J Epidemiol Glob Health       Date:  2020-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.